92 related articles for article (PubMed ID: 1316672)
1. CPF-DD is an inhibitor of infection by human immunodeficiency virus and other enveloped viruses in vitro.
Moore JP; Simpson G; McKeating JA; Burakoff SJ; Schreiber SL; Weiss RA
Virology; 1992 Jun; 188(2):537-44. PubMed ID: 1316672
[TBL] [Abstract][Full Text] [Related]
2. Prevention of HIV-1 infection and preservation of CD4 function by the binding of CPFs to gp120.
Finberg RW; Diamond DC; Mitchell DB; Rosenstein Y; Soman G; Norman TC; Schreiber SL; Burakoff SJ
Science; 1990 Jul; 249(4966):287-91. PubMed ID: 2115689
[TBL] [Abstract][Full Text] [Related]
3. Inhibitors of the conformational switch involved in CD4 binding by the env glycoprotein gp120 from human immunodeficiency virus type 1 (HIV1).
Reed J; Kinzel V
Biochemistry; 1994 Sep; 33(36):10993-8. PubMed ID: 8086417
[TBL] [Abstract][Full Text] [Related]
4. Multiple antiviral activities of cyanovirin-N: blocking of human immunodeficiency virus type 1 gp120 interaction with CD4 and coreceptor and inhibition of diverse enveloped viruses.
Dey B; Lerner DL; Lusso P; Boyd MR; Elder JH; Berger EA
J Virol; 2000 May; 74(10):4562-9. PubMed ID: 10775592
[TBL] [Abstract][Full Text] [Related]
5. Molecular structures of CPF-dipeptides, inhibitors for the binding of CD4 with gp120.
Venkatramani L; Hossain MB; Van der Helm D
Int J Pept Protein Res; 1994 Jun; 43(6):520-8. PubMed ID: 7928082
[TBL] [Abstract][Full Text] [Related]
6. RD6-2198, a novel betain-type fluoroalkylated oligomer, inhibits the replications of human immunodeficiency virus type 1 and other enveloped viruses.
Fujiwara M; Ashida N; Okamoto M; Mizuta T; Ide T; Hanasaki Y; Katsuura K; Sawada H; Shigeta S; Konno K; Yokota T; Baba M
Antiviral Res; 1998 May; 38(2):141-9. PubMed ID: 9707376
[TBL] [Abstract][Full Text] [Related]
7. The alpha-glucosidase inhibitor N-butyldeoxynojirimycin inhibits human immunodeficiency virus entry at the level of post-CD4 binding.
Fischer PB; Collin M; Karlsson GB; James W; Butters TD; Davis SJ; Gordon S; Dwek RA; Platt FM
J Virol; 1995 Sep; 69(9):5791-7. PubMed ID: 7543588
[TBL] [Abstract][Full Text] [Related]
8. Activation and Inactivation of Primary Human Immunodeficiency Virus Envelope Glycoprotein Trimers by CD4-Mimetic Compounds.
Madani N; Princiotto AM; Zhao C; Jahanbakhshsefidi F; Mertens M; Herschhorn A; Melillo B; Smith AB; Sodroski J
J Virol; 2017 Feb; 91(3):. PubMed ID: 27881646
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of Human Immunodeficiency Virus Type 1 Entry by a Keggin Polyoxometalate.
Wang X; Wang J; Zhang W; Li B; Zhu Y; Hu Q; Yang Y; Zhang X; Yan H; Zeng Y
Viruses; 2018 May; 10(5):. PubMed ID: 29772712
[TBL] [Abstract][Full Text] [Related]
10. Dissociation of gp120 from HIV-1 virions induced by soluble CD4.
Moore JP; McKeating JA; Weiss RA; Sattentau QJ
Science; 1990 Nov; 250(4984):1139-42. PubMed ID: 2251501
[TBL] [Abstract][Full Text] [Related]
11. HIV-1 gp 120 blocks jacalin-induced proliferative response in CD4+ T cells: jacalin as a useful surrogate marker for qualitative and quantitative deficiency of CD4+ T cells in HIV-1 infection.
Tamma SM; Oyaizu N; McCloskey TW; Kalyanaraman VS; Pahwa S
Clin Immunol Immunopathol; 1996 Sep; 80(3 Pt 1):290-7. PubMed ID: 8811050
[TBL] [Abstract][Full Text] [Related]
12. Phosphorothioate oligodeoxycytidine interferes with binding of HIV-1 gp120 to CD4.
Stein CA; Neckers LM; Nair BC; Mumbauer S; Hoke G; Pal R
J Acquir Immune Defic Syndr (1988); 1991; 4(7):686-93. PubMed ID: 1711118
[TBL] [Abstract][Full Text] [Related]
13. Polyclonal immunoglobulin G from patients neutralizes human immunodeficiency virus type 1 primary isolates by binding free virions, but without interfering with an initial CD4-independent attachment of the virus to primary blood mononuclear cells.
Burrer R; Haessig-Einius S; Aubertin AM; Moog C
J Virol; 2003 Nov; 77(21):11385-97. PubMed ID: 14557624
[TBL] [Abstract][Full Text] [Related]
14. Resistance of primary isolates of human immunodeficiency virus type 1 to neutralization by soluble CD4 is not due to lower affinity with the viral envelope glycoprotein gp120.
Turner S; Tizard R; DeMarinis J; Pepinsky RB; Zullo J; Schooley R; Fisher R
Proc Natl Acad Sci U S A; 1992 Feb; 89(4):1335-9. PubMed ID: 1741386
[TBL] [Abstract][Full Text] [Related]
15. Envelope glycoprotein incorporation, not shedding of surface envelope glycoprotein (gp120/SU), Is the primary determinant of SU content of purified human immunodeficiency virus type 1 and simian immunodeficiency virus.
Chertova E; Bess JW; Crise BJ; Sowder II RC; Schaden TM; Hilburn JM; Hoxie JA; Benveniste RE; Lifson JD; Henderson LE; Arthur LO
J Virol; 2002 Jun; 76(11):5315-25. PubMed ID: 11991960
[TBL] [Abstract][Full Text] [Related]
16. Cytolysis by CCR5-using human immunodeficiency virus type 1 envelope glycoproteins is dependent on membrane fusion and can be inhibited by high levels of CD4 expression.
LaBonte JA; Madani N; Sodroski J
J Virol; 2003 Jun; 77(12):6645-59. PubMed ID: 12767984
[TBL] [Abstract][Full Text] [Related]
17. HIV-1 R5 Macrophage-Tropic Envelope Glycoprotein Trimers Bind CD4 with High Affinity, while the CD4 Binding Site on Non-macrophage-tropic, T-Tropic R5 Envelopes Is Occluded.
Quitadamo B; Peters PJ; Repik A; O'Connell O; Mou Z; Koch M; Somasundaran M; Brody R; Luzuriaga K; Wallace A; Wang S; Lu S; McCauley S; Luban J; Duenas-Decamp M; Gonzalez-Perez MP; Clapham PR
J Virol; 2018 Jan; 92(2):. PubMed ID: 29118121
[TBL] [Abstract][Full Text] [Related]
18. M48U1 CD4 mimetic has a sustained inhibitory effect on cell-associated HIV-1 by attenuating virion infectivity through gp120 shedding.
Selhorst P; Grupping K; Tong T; Crooks ET; Martin L; Vanham G; Binley JM; Ariën KK
Retrovirology; 2013 Feb; 10():12. PubMed ID: 23375046
[TBL] [Abstract][Full Text] [Related]
19. Aurothiolates inhibit HIV-1 infectivity by gold(I) ligand exchange with a component of the virion surface.
Okada T; Patterson BK; Ye SQ; Gurney ME
Virology; 1993 Feb; 192(2):631-42. PubMed ID: 8421903
[TBL] [Abstract][Full Text] [Related]
20. Factors underlying spontaneous inactivation and susceptibility to neutralization of human immunodeficiency virus.
Layne SP; Merges MJ; Dembo M; Spouge JL; Conley SR; Moore JP; Raina JL; Renz H; Gelderblom HR; Nara PL
Virology; 1992 Aug; 189(2):695-714. PubMed ID: 1386485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
